We spent six market pages establishing that a UKCA mark is worth almost nothing outside Britain. Then we read the same six regulators' rules for medicines, and found the opposite. The MHRA is named in four of them. In Saudi Arabia the United Kingdom is even in the pricing basket.
Every market page on this site tells a UK medical device manufacturer some version of the same bad news. Saudi Arabia closed its reliance route in 2020 and takes nobody's mark. The Emirati document list names EC, 510(k) and PMA and not UKCA. Türkiye deleted UK notified body certificates from its national system at the end of 2020. Nigeria promised recognition in a document that disclaims legal effect. South Africa's device list runs Australia, Brazil, Canada, EU, Japan, USA — no Britain. Only Egypt writes the UK mark into its own procedure.
So when we turned to medicines we expected the same picture. It is not the same picture. It is close to inverted, and the reason is structural rather than lucky: medicines regulators have spent fifteen years building formal reliance frameworks with named authorities, while device regulators mostly have not. When a regulator maintains a list of authorities it trusts, the MHRA is usually on it. When it does not maintain one, the UK has nothing to be on.
| Market | MHRA named? | In which document | What it actually buys you | CPP | UK in pricing basket |
|---|---|---|---|---|---|
| South Africa SAHPRA | Yes, twice over | Reliance guideline, version 5, 6 August 2025 — "Medicines and Health Products Regulatory Agency (MHRA (UK))", listed beside the two EU procedures and separately again through "WHO listed Authorities" | Access to the reliance route. Note the contrast with the same regulator's device list, which excludes the UK | Not mentioned — an approval by a recognised authority is the trigger | Not established |
| Saudi Arabia SFDA | Yes | Regulatory Framework for Drugs Approval, version 6.4, in force 1 October 2023 — stringent authorities are "USFDA, EMA, MHRA (UK), Swissmedic, Health Canada, TGA (Australia) and PMDA (Japan)" | The faster timetable: 280 working days instead of 405 for a new drug or biologic already approved by a stringent authority, and 168 on priority review | Not required at all — SFDA dropped it for new applications across every pathway | Yes — 1 of 16 |
| Egypt EDA | Yes — "UK" is third on the list | Note to Applicant, list of EDA reference countries 2024, effective 1 July 2024 — twenty-four countries, named one by one with no EU bloc entry | The verification route needs approval by two such authorities; the abridged route needs one. Egypt is the only market that names Britain for both medicines and devices | Required, for both reliance routes | Not established |
| Türkiye TİTCK | Yes, but narrowly | Marketing authorisation regulation, article 4, gazetted 11 December 2021 — the MHRA is named in the definition of a reference medicinal product, beside the Australian authority | Your UK-approved product can serve as the comparator for a generic application. It does not open a reliance route: Türkiye assesses nationally and inspects your site itself | Required, or equivalent proof of authorisation | No — basket is defined as EU members |
| Nigeria NAFDAC | No | Reliance procedure guideline, effective 10 September 2024 — the list reproduces the pre-2015 international definition in which the UK appeared only as an EU member state | Nothing. An MHRA certificate is accepted as a certificate, but it opens no reliance route and no collaborative procedure | Required, in WHO format, legalised at the Nigerian High Commission | Not established |
| United Arab Emirates EDE | Cannot be established | The decree-law of 2024 defines "reference countries" as those whose marketing approvals are recognised — and does not say which they are. No list is published on any UAE government site we could reach | Unknown. The concept exists in statute and is used in the pricing rules; the contents are administrative and unpublished | Required, per the WHO system, legalised at the UAE embassy | Referenced but unpublished |
Each row is traced to the regulator's own document, with the version and the date it took effect. Where a regulator publishes nothing, the cell says so — we have not filled it with a plausible answer.
At its meeting of 23 to 25 June 2025 the World Health Organization's advisory group recommended the MHRA for designation as a WHO Listed Authority — for medicines and for vaccines both, across marketing authorisation, vigilance, establishment licensing, inspection, laboratory testing and clinical trial oversight. WHO's own summary describes it as "a highly mature regulatory authority, fully aligned with the principles of Good Regulatory Practices".
It is a full designation, not a transitional one — the MHRA does not appear on WHO's transitional list, where Egypt and Nigeria's own authorities currently sit.
The practical consequence is this. Reliance frameworks written in the last few years increasingly include "WHO Listed Authorities" as a category rather than naming every regulator individually. Any framework drafted that way now captures the MHRA automatically. South Africa's does, which is why the MHRA qualifies there twice — once by name and once by category.
In Nigeria and the UAE, where Britain is absent or unpublished, the WHO designation is the strongest thing a UK applicant can put in front of a regulator. It is not a right. It is a properly sourced argument, and it did not exist eighteen months ago.
Not every absence is a decision. Two of the six show the difference clearly, and the drafting tells you which is which.
NAFDAC's trusted-authority list reproduces the old international definition word for word: the American authority, the European Commission, the Japanese ministry, then the European Free Trade Association through Swissmedic and Health Canada, then Australia, Iceland, Liechtenstein and Norway.
Britain was never on that list in its own right. It was on it as an EU member state, and it fell off the day it left. Nobody decided anything. Look at the shape of the list, though: Iceland, Liechtenstein and Norway are each named separately. There is a slot the United Kingdom would fit into, and it is empty.
The external reference pricing basket is not a list of countries. It is a rule: the source countries are "those determined from among EU members" — France, Spain, Italy, Portugal and Greece.
Because the basket is defined by a class rather than by name, the UK left it automatically and cannot return without an express amendment. And yet on the registration side Türkiye did the opposite: it bolted the MHRA expressly into the definition of a reference product, next to Australia, precisely so that UK comparators would survive. One ministry repaired the damage; another did not.
The framework document names the MHRA. A second current SFDA document does not, and the wording betrays exactly when it was written.
The Regulatory Framework for Drugs Approval, version 6.4, defines stringent authorities as "USFDA, EMA, MHRA (UK), Swissmedic, Health Canada, TGA (Australia) and PMDA (Japan)". But the data requirements for human drug submissions, updated in August 2025, still speaks of a "reference member state in EU, USA, Canada, Switzerland, Australia and Japan". No United Kingdom. That is a pre-Brexit formulation surviving in a live document.
Our reading is that the framework controls, because it is the instrument that governs pathway eligibility and it is the later text on the point. But a client cannot safely assert that to a reviewer without confirming it, and confirming it is a letter to SFDA rather than an argument from a website. It is on our list.
Why we publish an inconsistency rather than resolve it quietly. Because you will meet it. If your regulatory affairs manager reads the dossier guidance and concludes that the UK is not recognised, and your consultant reads the framework and says it is, both of them are reading a current SFDA document correctly. Knowing that in advance is worth more than a confident answer that turns out to be half-sourced.
If you make both, the order is not the same. For a device the strongest UK position is Egypt. For a medicine it is Saudi Arabia and South Africa, where MHRA approval buys a faster pathway outright.
SFDA has dropped the certificate of pharmaceutical product for new marketing authorisation applications across every pathway. Egypt, Türkiye, Nigeria and the UAE all still require one, and Nigeria wants it legalised at its High Commission.
The United Kingdom is one of sixteen benchmark countries. Your British price is an input to your Saudi price, and there are mandatory reductions afterwards — twenty-five per cent when the first generic arrives, twenty per cent for the first biosimilar.
In Nigeria and the UAE it is the only recognised credential the MHRA carries, and it is recent enough that it will not be in the file your counterparty is working from.
Defined in statute, used in the pricing rules, published nowhere we could find. Whether the UK is on it cannot be established from public sources — this is a finding, not a failure to look.
A newer version of the reliance procedure guideline exists, dated a year after the one we read. We could not retrieve it, and it is the single document that could change the Nigeria answer.
We confirmed Saudi Arabia and Türkiye from the regulators' own instruments. For the other three we found no published pricing document and are not repeating what the literature says.
Two Turkish instruments were read from legal-database reproductions rather than the official gazette. The law is primary; the host is not. We re-verify before quoting them in a client document.
Everything else on this page was read from the regulator's own domain, with the document code, version and effective date recorded in the table above.
This page is the comparative answer. The market-by-market detail for medicines — who may apply, the pathways and their published clocks, the fees, the pricing rules and the inspection question — is in preparation, market by market, on the same standard as the device pages: nothing published until it is traced to the regulator's own document and dated.
Saudi Arabia and the United Arab Emirates are first, because they are where the research already runs deepest. Ask us about any of the six today — the assessment covers a market whether or not its page exists yet, and for medicines the answer is often better than you expect.
If you hold an MHRA marketing authorisation, four of these six markets already have a name for it. That is worth two weeks and a written route before you take anyone's word for the fifth.
Or reach us directly — mail@bcabusiness.co.uk · +44 7342 901002 · WhatsApp
Re-checked quarterly and whenever a reliance framework is revised. Two items are on an active watch list: the newer Nigerian reliance guideline, and whether the Emirati reference list is ever published. If either moves, this page moves and the change is dated.